{"id":"budesonide-salmeterol-montelukast","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nervousness/anxiety"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"}]},"_chembl":{"chemblId":"CHEMBL1200681","moleculeType":"Small molecule","molecularWeight":"608.18"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Budesonide is an inhaled corticosteroid that suppresses inflammatory cytokines and immune cell recruitment in the airways. Salmeterol is a long-acting beta-2 agonist that relaxes bronchial smooth muscle and provides sustained bronchodilation. Montelukast is a cysteinyl leukotriene receptor antagonist that blocks inflammatory mediators involved in asthma pathogenesis, providing complementary anti-inflammatory and bronchodilatory effects.","oneSentence":"This combination reduces airway inflammation via corticosteroid action, dilates airways through beta-2 agonist stimulation, and blocks leukotriene-mediated inflammatory pathways.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:30.835Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Persistent asthma in patients not adequately controlled on inhaled corticosteroid and long-acting beta-2 agonist alone"},{"name":"Asthma with allergic or exercise-induced components"}]},"trialDetails":[{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT00471809","phase":"PHASE4","title":"Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)","status":"TERMINATED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2006-03","conditions":"Asthma","enrollment":210},{"nctId":"NCT00252863","phase":"PHASE3","title":"DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Asthma","enrollment":1600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Budesonide + Salmeterol + Montelukast","genericName":"Budesonide + Salmeterol + Montelukast","companyName":"National Heart, Lung, and Blood Institute (NHLBI)","companyId":"national-heart-lung-and-blood-institute-nhlbi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces airway inflammation via corticosteroid action, dilates airways through beta-2 agonist stimulation, and blocks leukotriene-mediated inflammatory pathways. Used for Persistent asthma in patients not adequately controlled on inhaled corticosteroid and long-acting beta-2 agonist alone, Asthma with allergic or exercise-induced components.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}